Tarsus Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
7analysts covering
FY Revenue (est.)
$713.6Mnext fiscal year
FY EPS (est.)
-$2.13next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
XDEMVY Net Product Sales Annually451.4MTarget: $670 million to $700 million
XDEMVY Gross Margin Quarterly93.0%
Target ECPs Prescribing Weekly Quarterly0.5
Watch Items
- TP-05 Phase 2 Calliope Trial Topline DataTrigger: First Half of 2027Action: Evaluate efficacy in tick mortality and safety profile to determine progression to Phase 3.
- TP-04 Phase 2 KORE Trial Topline DataTrigger: First Half of 2027Action: Assess reduction in inflammatory lesions and mite eradication to support Phase 3 design.
Research as of 19 Jun 2026